Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 250

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Spinocerebellar ataxias: prospects and challenges for therapy development

Open access
Ashizawa, Tetsuo, Öz, Gülin, Paulson, Henry L. · 2018 · Nature Reviews Neurology

Abstract

The spinocerebellar ataxias (SCAs) comprise more than 40 autosomal dominant neurodegenerative disorders that present principally with progressive ataxia. Within the past few years, studies of pathogenic mechanisms in the SCAs have led to the development of promising therapeutic strategies, especially for SCAs caused by polyglutamine-coding CAG repeats. Nucleotide-based gene-silencing approaches that target the first steps in the pathogenic cascade are one promising approach not only for polyglutamine SCAs but also for the many other SCAs caused by toxic mutant proteins or RNA. For these and other emerging therapeutic strategies, well-coordinated preparation is needed for fruitful clinical trials. To accomplish this goal, investigators from the United States and Europe are now collaborating to share data from their respective SCA cohorts. Increased knowledge of the natural history of SCAs, including of the premanifest and early symptomatic stages of disease, will improve the prospects for success in clinical trials of disease-modifying drugs. In addition, investigators are seeking validated clinical outcome measures that demonstrate responsiveness to changes in SCA populations. Findings suggest that MRI and magnetic resonance spectroscopy biomarkers will provide objective biological readouts of disease activity and progression, but more work is needed to establish disease-specific biomarkers that track target engagement in therapeutic trials. Together, these efforts suggest that the development of successful therapies for one or more SCAs is not far away.Advances in our understanding of the pathogenic mechanisms of spinocerebellar ataxias (SCAs) have resulted in the development of promising therapeutic strategies for these inherited neurodegenerative disorders. Here, Ashizawa and colleagues review the current progress and future challenges facing clinical trials of new therapies for the SCAs.Key pointsSpinocerebellar ataxias (SCAs) are a group of dominantly inherited degenerative disorders that principally involve the cerebellum and its connections.Insights into the pathogenic mechanisms of many SCAs have suggested promising routes to symptomatic and disease-modifying therapy.Clinical research consortia for SCAs have started international collaborations to share and analyse natural history data.The Scale for Assessment and Rating of Ataxia is the best validated clinical outcome assessment measure, but additional measures should be developed with improved responsiveness to changes that are directly relevant to patients’ lives.MRI and magnetic resonance spectroscopy have emerged as potentially powerful biomarkers for disease activities and progression, but target engagement biomarkers, especially molecular biomarkers in biofluids, are yet to be developed.Collective efforts in SCA clinical research within the past few years have improved the prospects for eventual successful therapeutic development for the SCAs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41582-018-0051-6

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 250

Metadata

Authors
Ashizawa, T., Öz, G., & Paulson, H. L.
Venue
Nature Reviews Neurology
Published
2018-08-21
Volume
14
Issue
10
Pages
590-605
ISSN
  • 1759-4758 (ISSN-L)
  • 1759-4766
OpenAlex
W2888648680
Cited by
250
References
8
FWCI
2.92
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Spinocerebellar ataxias: prospects and challenges for therapy development. https://app.cochat.ai/papers/10.1038/s41582-018-0051-6
The paper
Ashizawa, T., Öz, G., & Paulson, H. L. (2018). Spinocerebellar ataxias: prospects and challenges for therapy development. Nature Reviews Neurology. https://doi.org/10.1038/s41582-018-0051-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.